Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Advanced Breast Cancer
Interventions: DRUG: ertumaxomab
Sponsor: Neovii Biotech
Collaborators: Fresenius Biotech North America